Synthesis and characterization of novel phosphonocarboxylate inhibitors of RGGT

Area of Science:

• Medicinal Chemistry
• Enzyme Inhibition
• Cancer Therapeutics

Background:

• Rab geranylgeranyl transferase (RGGT) is crucial for cellular processes and implicated in various cancers.
• Bisphosphonates are known anti-osteoporotic drugs, and their analogs, phosphonocarboxylates (PCs), are emerging as selective RGGT inhibitors.

Purpose of the Study:

• To synthesize and biologically characterize novel phosphonocarboxylate (PC) analogs as selective inhibitors of Rab geranylgeranyl transferase (RGGT).
• To explore lipophilic derivatives and identify compounds with improved potency and selectivity.
• To gain insights into the structural requirements for RGGT inhibition and report the first phosphonocarboxylate-derived GGPPS inhibitor.

Main Methods:

• Synthesis of a new panel of phosphonocarboxylate (PC) compounds, including lipophilic derivatives.
• Biological characterization of synthesized compounds to assess RGGT inhibitory activity.
• Evaluation of selectivity against prenyl pyrophosphate synthases and investigation of structure-activity relationships.

Main Results:

• Identification of a novel PC inhibitor with potency comparable to leading published compounds.
• Demonstration of enhanced selectivity of the new inhibitor towards RGGT over prenyl pyrophosphate synthases.
• Elucidation of structural requirements, indicating that only analogs of 3rd generation bisphosphonates effectively inhibit RGGT.
• Discovery of the first phosphonocarboxylate-derived inhibitor of geranylgeranyl pyrophosphate synthase (GGPPS).

Conclusions:

• Phosphonocarboxylate analogs represent a promising class of selective RGGT inhibitors for potential cancer therapy.
• The identified compounds offer improved potency and selectivity, warranting further investigation.
• Structural insights guide the design of next-generation RGGT and GGPPS inhibitors.